Lynparza (Olaparib) is indicated for treatment(s) of:
I. Ovarian Cancer
II. Metastatic Breast Cancer
III. Pancreatic cancer
a. I only
b. III only
c. I and II only
d. II and III only
e. All
Answer: (e). All. Lynparza (Olaparib) is an inhibitor of the mammalian polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme. Lynparza (Olaparib) tablets for oral administration contain 100 mg or 150 mg of Olaparib.
It is indicated for treatments of:
1. First-Line Maintenance Treatment Of BRCA-Mutated Advanced Ovarian Cancer
2. Maintenance Treatment Of Recurrent Ovarian Cancer
3. Advanced gBRCA-Mutated Ovarian Cancer After 3 Or More Lines Of Chemotherapy
4. Germline BRCA-Mutated HER2-Negative Metastatic Breast Cancer
5. Maintenance Treatment Of gBRCA-Mutated Pancreatic cancer
The recommended dose of Lynparza (Olaparib) is 300 mg (two 150 mg tablets) taken orally twice daily, with or without food, for a total daily dose of 600 mg.
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Pneumonitis, fatigue, nausea, vomiting and fatal toxicity are reported side effects of drug.
Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.
Ready for the full prep?
Continue your preparation with full NAPLEX practice questions, question bank access, and study materials.
Go to NAPLEX Study Materials